2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 800

BMI, Occupational Activity, and Leisure-Time Physical Activity: an Exploration of Risk Factors and Modifiers for Knee Osteoarthritis
Abstract Number: 2395

Body Composition, Strength, and Function in Elderly Patients with Giant Cell Arteritis
Abstract Number: 478

Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis
Abstract Number: 2582

Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Abstract Number: 2072

Bone Formation and Resorption Are Both Increased in Autoimmune Arthritis
Abstract Number: 1010

Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies
Abstract Number: 271

Bone Marrow Lesions in Knees with Osteoarthritis: Can Parameters From Dynamic Contrast Enhancement Predict Change in Bone Marrow Lesion Volume or Knee Pain Change?
Abstract Number: 38

Bone Marrow Lesions On Magnetic Resonance Imaging Are Not Associated with Regions of Hypermetabolism in an Animal Model of Osteoarthritis
Abstract Number: 1958

Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Abstract Number: 2583

Bone Structure and Perfusion Quantification of Bone Marrow Edema and Pannus Tissue Areas in the Wrist of Patients with RA
Abstract Number: 125

Borderline Right Ventricular Involvement in Patients with Systemic Sclerosis without Pulmonary Hypertension
Abstract Number: 295

Brain Biopsy Diagnosis in Magnetic Resonance Imaging Negative Childhood Primary Angiitis of the Central Nervous System
Abstract Number: 587

Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis
Abstract Number: 2525

Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants
Abstract Number: 2526

Bruton′s Tyrosine Kinase and Calreticulin: A Novel Interaction with Implications for Inflammatory and Autoimmune Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].